-
Mashup Score: 5Immunology’s Next Frontier - 16 hour(s) ago
Twenty years ago, Tim Radstake, M.D., saw history in the making – the results of a new treatment for patients with rheumatoid arthritis (RA), a chronic, autoimmune disease. At the hospital where he worked at the time, the treatment was administered to one of its very first patients. Later, the patient’s husband came back, filled with emotion. “When we saw him, everyone feared something was wrong, but what actually happened was his wife was able to do something she hadn’t done in years – get out of
Source: www.abbvie.comCategories: General Medicine News, PayerTweet
-
Mashup Score: 2AbbVie Presents New Data Supporting Leading Gastroenterology Portfolio at 2024 Digestive Disease Week® - 18 hour(s) ago
– AbbVie will present 15 abstracts, including three oral presentations, in Crohn’s disease and ulcerative colitis reinforcing AbbVie’s commitment to advancing the standards of care in inflammatory…
Source: news.abbvie.comCategories: General Medicine News, PayerTweet
-
Mashup Score: 4Tips for an Effective IBD Doctor-Patient Relationship - 4 day(s) ago
Dr. Verena Schick, a gastroenterologist from Germany, shares the importance of IBD patients partnering with their doctors.“Gutsy IBD Conversations” is a vide…
Source: www.youtube.comCategories: General Medicine News, PayerTweet
-
Mashup Score: 13
– Collaboration to leverage AbbVie’s psychiatry expertise and Gilgamesh’s innovative research platform to develop next-generation neuroplastogens for the treatment of psychiatric disorders NORTH…
Source: news.abbvie.comCategories: General Medicine News, PayerTweet
-
Mashup Score: 10Get Involved WOCD2024 - 10 day(s) ago
Last year, we celebrated the 11th World Ovarian Cancer Day, and it was a phenomenal success thanks to your support! Our outreach on social media channels alone touched over 200 million people, an incredible achievement amplified manyfold by the tireless efforts of our partner organizations and spons
Source: worldovariancancercoalition.orgCategories: General Medicine News, PayerTweet
-
Mashup Score: 17
New state-of-the-art research and development (R&D) facility at Ludwigshafen to expand discovery and development of new medicines across core therapeutic areas Investment reinforces the importance…
Source: news.abbvie.comCategories: General Medicine News, PayerTweet-
This week, our Chief Operations Officer & Chief Scientific Officer joined local Rhineland-Palatinate leaders at the groundbreaking for LUnA, our new R&D building in Ludwigshafen, Germany, where we’ve invested 150 million euros in #innovation & #research. https://t.co/wrAQWscydB https://t.co/l3QkTIQEv8
-
-
Mashup Score: 3Environmental, Social & Governance - 18 day(s) ago
We are advancing environmental, social and governance (ESG) initiatives that contribute to the sustainable growth of our company so that we can create positive impact for generations to come. Our ESG framework is built around three pillars that were developed based on our six core material drivers: product innovation, human capital management, product quality and safety, business ethics, patient health and engagement, and patient access and affordability.
Source: www.abbvie.comCategories: General Medicine News, PayerTweet
-
Mashup Score: 9AbbVie Reports First-Quarter 2024 Financial Results - 22 day(s) ago
Reports First-Quarter Diluted EPS of $0.77 on a GAAP Basis, an Increase of 492.3 Percent; Adjusted Diluted EPS of $2.31, a Decrease of 6.1 Percent; These Results Include an Unfavorable Impact of $0.08
Source: news.abbvie.comCategories: General Medicine News, PayerTweet
-
Mashup Score: 3
The Investor Relations website contains information about AbbVie’s business for stockholders, potential investors, and financial analysts.
Source: investors.abbvie.comCategories: General Medicine News, PayerTweet
-
Mashup Score: 5AbbVie Reports First-Quarter 2024 Financial Results - 22 day(s) ago
Reports First-Quarter Diluted EPS of $0.77 on a GAAP Basis, an Increase of 492.3 Percent; Adjusted Diluted EPS of $2.31, a Decrease of 6.1 Percent; These Results Include an Unfavorable Impact of $0.08
Source: news.abbvie.comCategories: General Medicine News, PayerTweet
People living with autoimmune diseases often go through a trial-and-error process to find the right treatment. Our #scientists are making big bets in research to help match the right patients to the right therapies at the right time. Explore: https://t.co/kLmJhaiyv6 #WorldIBDDay https://t.co/sNhNS6MrTj